Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D
May 24 2018 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it
has bolstered its efforts to attract partnerships and
collaborations and increase non-dilutive funding with the hiring of
an accomplished business development leader and the promotion of a
key R&D leader.
Mr. Shawn D. Bridy joins Inovio as Vice
President of Business Development reporting to Dr. J. Joseph Kim,
President & CEO. Mr. Bridy has more than 20 years of
business development & licensing, commercial strategy, and
transaction experience in the life sciences industry. He previously
held strategic business development roles at large pharma companies
and smaller biotechs including GSK, Elan, BTG plc and
Immunome. Most recently he was Managing Director of Bridy
Advisors, a top-tier strategic and operational advisory company.
Mr. Bridy has an MA in Biology and an MBA in Finance from Villanova
University.
Inovio has also promoted Dr. Kate E. Broderick,
Ph.D., to Vice President, Preclinical Research & Development
reporting to Dr. Laurent Humeau, Senior Vice President, R&D. In
her new position, Dr. Broderick will continue to spearhead Inovio’s
efforts to secure non-dilutive strategic R&D funding
opportunities to support the research and clinical testing of
Inovio’s candidate vaccines. Dr. Broderick has previously led
Inovio’s efforts to receive numerous grants from the U.S. National
Institutes of Health and Department of Defense as well from other
government and non-governmental organizations. She recently
led Inovio’s efforts to secure a $56 million funding from the
Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate
DNA vaccine candidates for Lassa fever and MERS through Phase 2
clinical testing. She will also be responsible for the
oversight of a diverse preclinical R&D team encompassing
discovery and development research, as well as operations, research
DNA manufacturing and next-generation device development. She
earned her Ph.D. at the University of Glasgow, Scotland.
Dr. Broderick recently participated in World
Health Organization (WHO) advisory panel in Geneva on “Product
Development & Programmatic Considerations for Nucleic
Acid-based Vaccines,” where she highlighted Inovio’s emerging
infectious disease vaccine portfolio, which includes the company’s
vaccine for Ebola.
Dr. J. Joseph Kim, Inovio’s President & CEO,
said, “While we have a strong record of performance in attracting
commercial partners such as MedImmune/AstraZeneca, Genentech/Roche
and Regeneron and have secured significant non-dilutive funding in
the past several years, hiring and promoting these two business and
scientific leaders will accelerate and expand those efforts going
forward. Kate and Shawn will play important roles in the growth of
Inovio as we partner assets and secure funding to support the
advancement of Inovio’s immunotherapies and vaccines.”
About Inovio Pharmaceuticals,
Inc.
Inovio is a late-stage biotechnology company
focused on the discovery, development, and commercialization of DNA
immunotherapies that transform the treatment of cancer and
infectious diseases. Inovio’s proprietary platform technology,
ASPIRE, applies next-generation antigen sequencing and DNA delivery
to activate potent immune responses to targeted diseases. The
technology functions exclusively in vivo, and has been demonstrated
to consistently activate robust and fully functional T cell and
antibody responses against targeted cancers and pathogens. Inovio
is the only immunotherapy company that has reported generating T
cells whose killing capacity correlates with relevant clinical
outcomes. Inovio’s most advanced clinical program, VGX-3100, is in
Phase 3 for the treatment of HPV-related cervical precancer. Also
in development are Phase 2 immuno-oncology programs targeting head
and neck cancer, bladder cancer, and glioblastoma, as well as
platform development programs in hepatitis B, Zika, Ebola, MERS,
and HIV. Partners and collaborators include MedImmune, Regeneron,
Roche/Genentech, ApolloBio Corporation, The Wistar Institute,
University of Pennsylvania, the Parker Institute for Cancer
Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life
Sciences, Drexel University, NIH, HIV Vaccines Trial Network,
National Cancer Institute, U.S. Military HIV Research Program, and
Laval University. For more information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and our plans and expectations regarding
partnerships. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by us or our collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that we and our collaborators hope to
develop, issues involving product liability, issues involving
patents and whether they or licenses to them will provide us with
meaningful protection from others using the covered technologies,
whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand
claims of invalidity and whether we can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
our technology by potential corporate or other partners or
collaborators, capital market conditions, the impact of government
healthcare proposals and other factors set forth in our Annual
Report on Form 10-K for the year ended December 31, 2017, our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2018
and other regulatory filings we make from time to time. There can
be no assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
CONTACTS: Investors: Ben
Matone, Inovio, 484-362-0076, ben.matone@inovio.comMedia: Jeff
Richardson, Inovio, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024